Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Taylor
Anne L
AL
National Center of Excellence in Women's Health, University of Minnesota Medical School, Minneapolis, MN 55455, USA. taylo135@umn.edu
Wright
Jackson T
JT
D001741:Black or African American; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D005006:Ethnicity; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D006977:Hypertension, Renal; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000517:prevention & control*; D044469:Racial Groups
D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents